ITI’s Dr. Teri Heiland, CSO named as Top 10 vaccine influencers in MD
Featured Highlights Press10 International Vaccine Influencers Who Exemplify Maryland’s Leading Role in Public Health Immunomic Therapeutics is listed as one of the Top 10 Maryland Vaccine Influencers in public health and Dr.Read moreITI’s CEO to Participate in Panel at MD Life Sciences’ Bio Innovation Conference Meeting 2020
Featured Press Press ReleasesSeptember 29, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate in a panel at the MD Life Sciences Bio InnovationRead moreITI’s VP to Participate at Precision Medicine’s Webinar on Oncolytic Therapeutic Development
Featured Highlights Press Press ReleasesSeptember 23, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will be participating in Precision Medicine’s webinar on utilizing liquid biopsy toRead more5th International Virtual Conference on Cancer Research & Development 2020, Oct. 26-28
Events Past EventsCancer R&D 2020 Symposium ITI is proud to be participating in the 5th International Conference on Cancer Research and Drug Development 2020, a three-day symposium bringing cutting edge developments inRead moreITI to Participate at World Vaccine Congress Washington 2020
Featured Press Press ReleasesROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI) announced today that it will participate at the World Vaccine Congress Washington being held virtually September 28-October 1, 2020. Andrew Eisen, MD, Ph.D.,Read moreImmunomic Therapeutics Inc. Expands into South Korea
Featured Highlights Press Press ReleasesSeoul Office Will Be Opening to Develop Immunomic Therapeutics Investigational Cell Therapy for Brain Cancer September 10, 2020 08:00 AM Eastern Daylight Time SEOUL--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-heldRead more- Featured Press Press ReleasesImmunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM~25-35 % survival over 5 years from diagnosis in vaccinated GBMRead more
Register Now: Dr. Teri Heiland joins a panel discussion: Past, Present and Future of Immuno-oncology
Events Past Events PressREGISTER NOW Oncology Central powered by Future Science Group presents the panel discussion: Past, Present and Future of Immuno-oncology DATE: September 23, 2020 TIME: 10:00AM EDT/7:00AM PDT/15:00PM BST This panelRead moreKeystone eSymposia: Advances in Cancer Immunotherapy Poster Presentation
PostersPoster Title: Glypican-3-LAMP: A novel DNA vaccine for liver cancer immunotherapy Presentation Date: August 17-18, 2020 3:30-5PM EST Download poster here.Read moreDC Inno’s on Fire names Immunomic Therapeutics a Winner
Events Featured HighlightsITI was chosen as one of DC Inno’s on Fire Winners for 2020 alongside Emergent Biosolutions, Novavax and Viela Bio. Check it out… https://www.americaninno.com/dc/50-on-fire/meet-dc-innos-2020-Inno-on-fire DC Inno is your source forRead moreReplicate Bioscience and ITI Form Collaboration to Combat Infectious Diseases and Cancers
Featured Press Press Releases-Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technology and grow operations- June 24, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md. &Read more- Featured Press Press Releases-First-in-Human Phase I study is anticipated to commence in 2021- June 16, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneeringRead more